ACIP Recommends Use of Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born ...

Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV) ...

Respiratory syncytial virus (RSV) is a leading cause of severe illness in infants, with no effective treatment. Results of a phase 2 trial suggested that ziresovir may have efficacy in the treatmen ...

For 60-Plus Years, Respiratory Syncytial Virus (RSV) Vaccines Have Evaded Scientists. But Now That’s Changed [Sponsored] ...

The burden of respiratory syncytial virus (RSV) in Germany: a comprehensive data analysis suggests underdetection of hospitalisations and deaths in adults 60 years and older. Infect Dis Ther.

Parents are being warned to look out for symptoms of Respiratory Syncytial Virus (RSV) in their newborn babies as the NHS prepares for overcrowding this winter. The infection causes mild, cold ...

AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices Over 13 million adults aged 50-59 ...

Learn about different kinds of tests for RSV (respiratory syncytial virus), and find out when doctors use them to diagnose an adult, baby, or older child.

A highly anticipated new shot that can protect newborns from the ravages of respiratory syncytial virus may not be accessible for some families this season because of uncertainties about insurance ...

Army scientists' technique for early detection of sepsis in burn patients submitted to FDA By Paul Lagasse, USAMRDC Public Affairs Office September 10, 2024 ...